Anastasia Chrysovalantou Chatziioannou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Anastasia Chrysovalantou Chatziioannou has a total of 129 co-authors. Here are the top co-authors by number of shared publications:
- Pekka Keski-Rahkonen
Nutrition and Metabolism Branch International Agency for Research on Cancer Lyon France
14 shared publications - Agnetha Linn Rostgaard-Hansen
Danish Cancer Society 22 Copenhagen
13 shared publications - Anne Tjønneland
Danish Cancer Institute, Copenhagen, Denmark
13 shared publications - Fulvio Ricceri
Centre for Biostatistics, Epidemiology, and Public Health, Department of Clinical and Biological Sciences, University of Turin, Orbassano, Turin, Italy
13 shared publications - Maria-Jose Sánchez
Escuela Andaluza de Salud Pública (EASP), 18011 Granada, Spain
13 shared publications - Mazda Jenab
International Agency for Research on Cancer (IARC/WHO), Nutrition and Metabolism Branch, Lyon, France
13 shared publications
Latest Publications
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Consistent Metabolomic and Genetic Evidence Supports Acisoga as a Key Contributor to Colorectal Neoplasia Progression
Supplementary Table S5. Predixcan in Previous Acisoga Studies. Previously reported SNPs associated with circulating Acisoga levels their evaluation in the present study using S-PrediXcan and CRC GWAS meta-analysis summary statistics
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Consistent Metabolomic and Genetic Evidence Supports Acisoga as a Key Contributor to Colorectal Neoplasia Progression
Supplementary Table S5. Predixcan in Previous Acisoga Studies. Previously reported SNPs associated with circulating Acisoga levels their evaluation in the present study using S-PrediXcan and CRC GWAS meta-analysis summary statistics
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Consistent Metabolomic and Genetic Evidence Supports Acisoga as a Key Contributor to Colorectal Neoplasia Progression
Supplementary Table S4. SNPs and weights (betas) and reference and alternative alelles of the LASSO model.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Consistent Metabolomic and Genetic Evidence Supports Acisoga as a Key Contributor to Colorectal Neoplasia Progression
Supplementary Table S4. SNPs and weights (betas) and reference and alternative alelles of the LASSO model.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Consistent Metabolomic and Genetic Evidence Supports Acisoga as a Key Contributor to Colorectal Neoplasia Progression
Supplementary Figure S5. Manhattan plot displaying the association between Acisoga levels and SNPs. The p-values are shown on a -log10 scale, with reference a line indicating the suggestive significance threshold (5 x 10-6).
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Consistent Metabolomic and Genetic Evidence Supports Acisoga as a Key Contributor to Colorectal Neoplasia Progression
Supplementary Figure S5. Manhattan plot displaying the association between Acisoga levels and SNPs. The p-values are shown on a -log10 scale, with reference a line indicating the suggestive significance threshold (5 x 10-6).
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Consistent Metabolomic and Genetic Evidence Supports Acisoga as a Key Contributor to Colorectal Neoplasia Progression
Supplementary Figure S6. LocusZoom plots genome-wide significant associations (p < 5 × 10-6) of Acisoga levels with genetic variants. Each panel displays the genomic region surrounding the lead SNP highlighting nearby genes.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Consistent Metabolomic and Genetic Evidence Supports Acisoga as a Key Contributor to Colorectal Neoplasia Progression
Supplementary Figure S6. LocusZoom plots genome-wide significant associations (p < 5 × 10-6) of Acisoga levels with genetic variants. Each panel displays the genomic region surrounding the lead SNP highlighting nearby genes.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Consistent Metabolomic and Genetic Evidence Supports Acisoga as a Key Contributor to Colorectal Neoplasia Progression
Supplementary Figure S1. MS/MS spectra of Acisoga. MS/MS spectra of the metabolite annotated as N-(3-acetamidopropyl)pyrrolidin-2-one (Acisoga) in pooled study samples (collision energies 15 eV and 30 eV, respectively) and in the authentic chemical standard. The fragmentation patterns show overlapping peaks between study samples and the standard, supporting annotation at MSI Level 1.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Consistent Metabolomic and Genetic Evidence Supports Acisoga as a Key Contributor to Colorectal Neoplasia Progression
Supplementary Figure S1. MS/MS spectra of Acisoga. MS/MS spectra of the metabolite annotated as N-(3-acetamidopropyl)pyrrolidin-2-one (Acisoga) in pooled study samples (collision energies 15 eV and 30 eV, respectively) and in the authentic chemical standard. The fragmentation patterns show overlapping peaks between study samples and the standard, supporting annotation at MSI Level 1.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Consistent Metabolomic and Genetic Evidence Supports Acisoga as a Key Contributor to Colorectal Neoplasia Progression
Supplementary Table S1. Top-ranked metabolic features associated with colorectal neoplasia progression prior to multiple testing correction. Features with nominal p-values <0.01 from linear trend models across diagnostic groups are shown. Beta coefficients represent the direction and magnitude of association across disease progression. Direction indicates whether metabolite levels increase or decrease with advancing disease stage.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Consistent Metabolomic and Genetic Evidence Supports Acisoga as a Key Contributor to Colorectal Neoplasia Progression
Supplementary Table S1. Top-ranked metabolic features associated with colorectal neoplasia progression prior to multiple testing correction. Features with nominal p-values <0.01 from linear trend models across diagnostic groups are shown. Beta coefficients represent the direction and magnitude of association across disease progression. Direction indicates whether metabolite levels increase or decrease with advancing disease stage.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Consistent Metabolomic and Genetic Evidence Supports Acisoga as a Key Contributor to Colorectal Neoplasia Progression
Supplementary Figure S4. Supporting information for the annotations in EPIC. Supporting information for the annotations after re-analysing the pooled quality control sample of the EPIC study and the pure chemical standard for N-(3-acetamidopropyl)pyrrolidin-2-one. The top panels show the chromatograms of the selected chemical formula of the metabolite of interest (left) and the isotopic patterns (right; expected in red, observed in black). The bottom panels display the fragmentation patterns obtained at 5 V (left) and 10 V (right).
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Consistent Metabolomic and Genetic Evidence Supports Acisoga as a Key Contributor to Colorectal Neoplasia Progression
Supplementary Figure S4. Supporting information for the annotations in EPIC. Supporting information for the annotations after re-analysing the pooled quality control sample of the EPIC study and the pure chemical standard for N-(3-acetamidopropyl)pyrrolidin-2-one. The top panels show the chromatograms of the selected chemical formula of the metabolite of interest (left) and the isotopic patterns (right; expected in red, observed in black). The bottom panels display the fragmentation patterns obtained at 5 V (left) and 10 V (right).
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Consistent Metabolomic and Genetic Evidence Supports Acisoga as a Key Contributor to Colorectal Neoplasia Progression
Supplementary Figure S3. Forest plots of Previous Studies. Forest plot showing the odds ratios and 95% confidence intervals for metabolic features associated with Colorectal Cancer status. The results are compared with previous studies. Red squares represent the current study, while blue and green squares indicate findings from prior research. The “Compound” column lists the metabolite names or feature identifiers as reported in those previous studies, while “Mass@RT” corresponds to the matching metabolic features identified in our dataset. CRC: Colorectal Cancer, Precancerous Lesions (Low, Intermediate and High Risk Lesions).
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Consistent Metabolomic and Genetic Evidence Supports Acisoga as a Key Contributor to Colorectal Neoplasia Progression
Supplementary Figure S3. Forest plots of Previous Studies. Forest plot showing the odds ratios and 95% confidence intervals for metabolic features associated with Colorectal Cancer status. The results are compared with previous studies. Red squares represent the current study, while blue and green squares indicate findings from prior research. The “Compound” column lists the metabolite names or feature identifiers as reported in those previous studies, while “Mass@RT” corresponds to the matching metabolic features identified in our dataset. CRC: Colorectal Cancer, Precancerous Lesions (Low, Intermediate and High Risk Lesions).
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Consistent Metabolomic and Genetic Evidence Supports Acisoga as a Key Contributor to Colorectal Neoplasia Progression
Supplementary Table S2. Features comparison with previous studies. Each row represents a metabolite with its observed mass and retention time (RT), alongside the corresponding feature identified in our dataset. Differences in mass (ppm) and RT (seconds) are shown. The columns summarize findings from previous studies comparing metabolite levels in colorectal cancer (CRC) vs. control, and CRC-precancerous lesions. Values are reported as mean ratios with 95% confidence intervals. References include Geijsen et al. (2019), Alcolea et al. (2023), Rius-Sansalvador et al., and Gumpenberger et al. (2020).
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Consistent Metabolomic and Genetic Evidence Supports Acisoga as a Key Contributor to Colorectal Neoplasia Progression
Supplementary Table S2. Features comparison with previous studies. Each row represents a metabolite with its observed mass and retention time (RT), alongside the corresponding feature identified in our dataset. Differences in mass (ppm) and RT (seconds) are shown. The columns summarize findings from previous studies comparing metabolite levels in colorectal cancer (CRC) vs. control, and CRC-precancerous lesions. Values are reported as mean ratios with 95% confidence intervals. References include Geijsen et al. (2019), Alcolea et al. (2023), Rius-Sansalvador et al., and Gumpenberger et al. (2020).
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Consistent Metabolomic and Genetic Evidence Supports Acisoga as a Key Contributor to Colorectal Neoplasia Progression
Supplementary Figure S2. Stratified analysis of Acisoga levels across colorectal neoplasia stages. Log2-transformed Acisoga intensities across diagnostic groups (C, controls; LRL, low-risk lesions; IRL, intermediate-risk lesions; HRL, high-risk lesions; CRC, colorectal cancer), stratified by participant characteristics. a) Sex: males (purple triangles) and females (coral diamonds). b) Age: <61 years (blue triangles) and ≥61 years (light green diamonds). c) Body mass index (BMI): <27.7 kg/m² (orange triangles) and ≥27.7 kg/m² (dark pink triangles). d) Alcohol intake: <5.5 alcohol g/day (maroon triangles) and ≥5.5 alcohol g/day (dark green diamonds). Black circles represent mean intensities for all individuals.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Consistent Metabolomic and Genetic Evidence Supports Acisoga as a Key Contributor to Colorectal Neoplasia Progression
Supplementary Figure S2. Stratified analysis of Acisoga levels across colorectal neoplasia stages. Log2-transformed Acisoga intensities across diagnostic groups (C, controls; LRL, low-risk lesions; IRL, intermediate-risk lesions; HRL, high-risk lesions; CRC, colorectal cancer), stratified by participant characteristics. a) Sex: males (purple triangles) and females (coral diamonds). b) Age: <61 years (blue triangles) and ≥61 years (light green diamonds). c) Body mass index (BMI): <27.7 kg/m² (orange triangles) and ≥27.7 kg/m² (dark pink triangles). d) Alcohol intake: <5.5 alcohol g/day (maroon triangles) and ≥5.5 alcohol g/day (dark green diamonds). Black circles represent mean intensities for all individuals.